Biologic treatment options for Crohn's disease (CD) are increasing and providers will need enhanced support in integrating these therapies into routine practice. Using phase 3 clinical trial programs in CD, we have previously built and validated clinical decision support tools for achieving clinical remission (CREM) with vedolizumab and ustekinumab in CD.1-4 We now aim to develop a clinical decision support tool for infliximab in CD.
Trial registration: ClinicalTrials.gov NCT00094458 NCT02096861.
Copyright © 2022 AGA Institute. Published by Elsevier Inc. All rights reserved.